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ABSTRACT
TITLE:
 Hormone receptor status in Breast cancer in relation to Histological
grading, age and lymph node involvement.
AUTHOR:
 Dr.Rani Suganya, M.S., General Surgery Post Graduate III Year
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 Estrogen receptor, Progesterone receptor, HER 2/neu oncoprotein,
Grading, Lymphnode , Age.
BACKGROUND:
Aim of the study is to evaluate hormone receptor status and HER
2/neu in breast carcinoma by using immunohistochemical method and to
correlate with histological grade, age and lymphnode involvement in breast
cancer patients attending General Surgery OPD, Govt. Stanley Medical
College Hospital , Chennai.
RESULTS:
From the above study in a group of 50 breast cancer patients, we
found that Invasive Ductal Carcinoma-Nos type constituted the most
commonest histological variants. Regarding histological grade , Grade II
tumours was found to be commonest. Estrogen and progesterone receptor
positivity was found in about 70% of cases, whereas HER 2/neu positivity
was found in 36% of the tumours. Larger the tumour size lesser is the
expression of hormone receptor status. There is higher receptor expression
in nodal negative patienrs.HER 2/neu overexpression is found in about
64% of nodal positive patients. Higher the histological grade lower the
receptor positivity and greater the HER 2/neu overexpression. There is an
inverse relation between the receptor and HER 2/neu overexpresssion.
CONCLUSION:
Estrogen, Progesterone receptor positive tumours are more common
in the post menopausal women, tumours of more than 2cm in size,
Histological  grade I and in nodal negative patients. Oncoprotein
overexpression is common among the tumours of more than 2cm in size,
grade III tumours and in nodal positive patients. Hormone receptor and
oncoprotein expression has an inverse correlation with each other.
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INTRODUCTION 
Breast cancer is the major health problem for the women 
throughout the world. It accounts for 33% of all female cancers and 20% 
of cancer related deaths in women. Every year 9,00,000 new cases are 
diagnosed and causes approximately 3,76,000 deaths annually 
worldwide.  
In Chennai breast cancer accounts for 26.8% of all cancers in 
women. A few decades back breast carcinoma is more common in 
women above 50 years comprising about 65% to 70% with 30% to 35% 
of women were below 50 years of age. But at present the scenario has 
changed with increasing incidence below 50 years of age comprising of 
about 49%. Breast cancer scenario in India also shows a significant trend 
of increased incidence of breast cancer in much younger age than earlier. 
Management of breast carcinoma has evolved to include both 
surgery for local disease and medical therapy for systemic disease. 
Current treatment strategies take into account tumour cells, size and 
location of the tumour to guide treatment. At present, there are choices of 
conservative and reconstructive surgery which is more popular than 
mastectomy due to the availability of increased range of systemic, 
cytotoxic and hormonal drugs used in neoadjuvant and adjuvant settings. 
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Prognosis and management of breast carcinoma depends upon the 
histological type, grade, tumour size, nodal status, hormonal receptor 
status and HER-2/neu overexpression. 
Identification of biomarkers plays an important role in the 
prognosis and management of breast carcinoma. At the time of diagnosis, 
determination of hormonal status forms an important step in primary 
assessment. Identification of Estrogen and Progesterone receptor at the 
time of diagnosis plays a crucial role to plan for optimal treatment of 
breast carcinoma. 
Estrogen exposure is a well-established predictive and prognostic 
factor for developing ER-positive breast cancer. Estrogen is a steroid 
hormone. It has a proliferative effect on normal human mammary 
epithelium through its activation of Estrogen receptor, a nuclear hormone 
receptor. ER positivity is overexpressed in as many as 70% of breast 
cancers. Today, Estrogen receptor remains a very effective target for 
breast cancer treatment . ER/PR-positive tumours have a better prognosis 
than ER/PR-negative tumours. Hormone receptor test is done routinely 
since hormone treatment has fewer side effects and it prevents recurrence 
in about 25% of cases. 
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HER2 amplification or protein overexpression is associated with 
accelerated cell growth and proliferation. It is also associated with an 
increased risk of recurrence and shortened overall patient survival. The 
prognosis of HER-2/neu positive tumours are worse than HER2/neu 
negative tumours. It serves as a marker of aggressive disease and a 
biologic target for treatment. It is sensitive to treatment with monoclonal 
antibody Trastuzumab (Herceptin). 
Tumour grading is done on the basis of Bloom Richardson grading 
system. It grades breast carcinoma by adding up scores for tubule 
formation, nuclear pleomorphism and mitotic count each of which is 
given a score of 1 to  3.Receptor status together with tumour grade helps 
to categorize breast cancer into several molecular classes that have 
different prognosis and may have different responses to specific 
therapies. 
ER, PR and HER 2/neu receptors status are determined using 
immunohistochemistry method. Response to hormone therapy in ER/PR 
positive tumours implicate good prognosis. The relationship between ER, 
PR and HER 2/neu receptor status and tumour grading, lymph node status 
and age plays an important role in the management of carcinoma breast. 
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AIMS AND OBJECTIVES OF THE STUDY 
 
1. To evaluate ER, PR receptor status and HER 2/neu oncoprotein 
expression in carcinoma breast using immunohistochemical 
method. 
2. To evaluate tumour grading, lymph node status in 
histopathological specimen 
3. To correlate ER, PR and HER 2/neu status with lymph node, 
tumour grading and age of the patient. 
4. To evaluate occurrence of histological variants of carcinoma 
breast in patients attending OPD in Govt. Stanley Medical 
college Hospital. 
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REVIEW OF LITERATURE 
EMBRYOLOGY OF THE BREAST` 
 
 
 
 
A. TO D :  Stages In The Formation Of Duct System And Potential 
Glandular Tissue From The Epidermis. 
E : Eversion of the Nipple Near Birth. 
  
At about fifth or sixth week of fetal life, two ventral bands of 
thickened ectoderm develop called as milk line or mammary ridge 
extending from foregut to hindlimb. These may disappear after a short 
time except for a small portion which may persist in the pectoral region. 
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Ingrowth of ectoderm in each breast forms the primary bud. This primary 
bud inturn forms 15 to 20 secondary buds. Epithelial cords develops from 
the secondary bud and extends into the surrounding mesenchyme forming 
lactiferous ducts. These lactiferous ducts opens into the shallow 
mammary pits. In infancy proliferation of mesenchyme transforms the 
mammary pit into a nipple. At birth, breasts of both males and females 
are identical. 
FUNCTIONAL ANATOMY 
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The  female  breast  extends  from  the  level  of  second  or  third  rib  
superiorly to the level of sixth or seventh rib inferiorly. It extends 
transversely from the lateral border of sternum medially to the anterior 
axillary line laterally. The posterior surface of the breast lies on the fascia 
of the pectoralis major, serratus anterior and external oblique muscles and 
the upper extent of the rectus sheath. The retromammary bursa is present 
in between the investing fascia of the breast and the fascia of the 
pectoralis major muscles. The portion of the breast that lie across the 
anterior axillary fold is called the axillary tail of Spence 
The breast is composed of 15 to 20 lobes. Each lobes are composed 
of several lobules. Suspensory ligament of Cooper are fibrous connective 
tissue  that  pass  through  the  breast  tissue  to  the  dermis  to  provide  
structural support to the breast. Large volume of breast tissue are found in 
the upper outer quadrant than in any other quadrants. 
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NIPPLE AND AREOLA 
 
 
The nipple and areola complex is pigmented and corrugated. 
During puberty, the pigment over the nipple becomes darker and assumes 
an elevated configuration. During pregnancy, there is deepening of the 
pigmentation and the areola enlarges. Sweat glands, sebaceous glands 
and accessory glands are present in the areola and it produces small 
elevations on the surface of the areola and they are called as Montgomery 
tubercles. There are smooth muscle fibres that lie circumferentially in the 
dense connective tissue and longitudinally along the major ducts and 
extend in to the nipple. They are responsible for the nipple erection that 
occurs with various sensory stimuli. Moreover the tip of the nipple 
contains numerous sensory nerve endings and Meissner's corpuscles. This 
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sensory innervation is responsible for the initiation of chain of 
neurohumoral events when the infant sucks that results in milk letdown. 
BLOOD SUPPLY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A -  Direct mammary branches of the axillary artery. 
B - Branches of lateral thoracic artery. 
C - Perforating branches of internal thoracic artery. 
 
 
The principle blood supply are from 
1. Perforating branches of the internal mammary artery. 
2. Lateral branches of the posterior intercostals arteries. 
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3. Branches from the axillary artey including lateral thoracic artery 
and pectoral branch of thoracoacromial artery. 
4. Medial mammary artery is formed by the arborising branches of 
the internal mammary artery and second, third and fourth anterior 
intercostal perforators.  
5. The pectoralis major, pectoralis minor, serratus anterior and 
subscapularis muscle receive branches from the lateral thoracic 
artery. 
VENOUS DRAINAGE 
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The principle group of veins are 
1. Perforating branches of the internal thoracic vein. 
2. Perforating branches of the posterior intercostal veins. 
3. Tribuitaries of the axillary vein. 
4. Vertebral plexus of Batson invests the vertebra and extends from 
the base of the skull to the sacrum is responsible for the breast 
cancer metastases to the vertebrae, skull, pelvic bones and the 
brain. 
LYMPHATIC DRAINAGE 
The principle group of axillary lymph nodes are
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1. Axillary group or lateral group consists of 4 to 6 lymph nodes 
which lie on the medial or posterior aspect of the vein and receives 
lymphatic drainage from the upper extremity. 
2. External mammary or anterior or pectoral group consists of 5 to 6 
lymph nodes and lie along the lower border of pectoralis minor 
muscle and receive lymphatic drainage from the lateral aspect of 
the breast. 
3. The scapular or subscapular or posterior group consists of 5 to 7 
lymph nodes lies along the lateral border of the scapula and 
receives lymphatic from the lower posterior neck, posterior 
shoulder and posterior trunk. 
4. The central group consists of 3 to 4 lymph nodes and lie along the 
posterior border of the pectoralis minor muscle and receives 
lymphatics from the axillary, external mammary and the scapular 
group and also directly from the breast. 
5. The subclavicular group consists of 6 to 12 lymph nodes and lie 
along the superior and upper border of pectoralis minor muscle and 
receives lymphatics from the other axillary groups. 
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6. The interpectoral group or Rotter’s nodes consists of 1 to 4 lymph 
nodes lies between the pectoralis major and minor muscle and 
receive lymphatics from the breast. 
The lymph nodes are grouped into levels in relation to the pectoralis 
minor 
 
 
 
 
 
 
 
 
1. Level I lymph nodes are located lateral to the lower border of 
pectoralis minor muscle and includes axillary, external mammary 
and scapular groups. 
2. Level II lymph nodes are located posterior to pectoralis minor 
muscle and includes central and interpectoral groups. 
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3. Level III lymph nodes are located superior to medial border of 
pectoralis minor muscle and includes subclavicular group. 
 The lymphatic plexus of the breast arises in the interlobular 
connective tissue and major lactiferous duct and traverses to the 
subareolar  plexus  of  Sappey.  Efferents  from  the  breast  travel  along  the  
lateral border of the pectoralis major muscle  and pierces the 
clavipectoral fascia to reach the external mammary group. Some reach 
the axillary and the scapular group. 75% of the lymphatics from the 
breast reach the axillary lymph nodes. Rest of the lymphatics reach the 
internal mammary lymph nodes, primarily from the medial aspect of the 
breast.   
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NERVE SUPPLY 
 
 
 
1. Lateral cutaneous branches of the third to sixth intercostals nerves 
provide sensory supply to the breast and the anterolateral chest 
wall. 
2. Cutaneous branches of the cervical plexus specifically the anterior 
branches of the supraclavicular nerves supply a limited area of the 
skin of the breast. 
3. Intercostobrachial nerve, lateral cutaneous branch of the second 
intercostals nerve supplies the medial aspect of the upper arm, 
which is often encountered in axillary dissection. 
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MICROSCOPIC ANATOMY 
 
 
 
 
 
 
 
 
 
The mature breasts composed of 
1. Glandular epithelium 
2. Fibrous stroma and supporting structures 
3. Fat and infiltrating cells including lymphocytes and 
macrophages. 
The glandular apparatus of the breast is consists of branching 
system of lactiferous ducts extending outwards and downwards from the 
nipple areolar complex. These ducts ends in cluster of spaces called as 
terminal ductules or acini. The terminal ductules together with small 
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efferent ductules form the lobules. These are the milk forming glands. 
The lactiferous ducts in the subareolar region widens to form the 
lactiferous sinuses which opens through 10 to 15 orifices in the nipple. 
These ducts are lined by low columnar or cuboidal epithelium. 
The branching ductal system is surrounded by myoepithelial cells 
which have contractile properties that propel the milk formed in the 
lobules towards the nipple. The basement membrane surrounds the 
epithelial and myoepithelial cells of the ducts and is made up of laminin, 
type IV collagen and proteoglycans. The basement membrane is 
important in differentiating between carcinoma in situ and invasive 
cancer. 
PHYSIOLOGY 
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Hormones like estrogen, progesterone, prolactin, thyroid hormone, 
oxytocin, cortisol and growth hormone are essential for the normal 
development and function of the breast. Development of ductal 
epithelium is initiated by estrogen and differentiation of the ductal 
epithelium and the lobular development  by the progesterone hormone. 
The hormonal stimulus for lactogenesis is prolactin.The release of 
estrogen and progesterone from the ovaries are stimulated by 
gonadotropic hormones like luteinizing hormone (LH) and follicle 
stimulating hormone (FSH). Basophilic cells of anterior pituitary secrete 
LH and FSH, which is regulated by the release of gonadotropin releasing 
hormone (GnRH) from the hypothalamus, which in turn is controlled by 
the positive and negative feedback effects of the circulating estrogen and 
progesterone. 
After birth, circulating estrogen and progesterone levels fall and 
remain low till puberty, due to the effect of negative feedback on the 
hypothalamic pituitary axis. At puberty, there is decrease in the 
sensitivity of the negative feedback on the hypothalamic pituitary axis 
and increase sensitivity to positive feedback by estrogen hormones. These 
in turn stimulate the secretion of GnRH, FSH, LH and ultimately the 
secretion of estrogen and progesterone, estabilishing the menstrual cycle.  
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During prepuberty the breast is composed of fibrous stroma and 
few ducts lined with epithelium. With the onset of menstrual cycle, there 
is commencement of breast engorgement and duct epithelium 
proliferation. Breast development are initiated by low amplitude of 
pituitary gonadotrophins, which increase estradiol level. This causes 
increase in deposition of fat, branching system of ducts and lobular units. 
During pregnancy, the circulating ovarian and placental estrogen 
and progesterone causes the breast to enlarge with the proliferation of 
ductal and lobular epithelium. The accessory glands of Montgomery  
becomes prominent and the areolar skin darkens. The minor ducts 
develop and branch during the first and second trimester. During the third 
trimester colostrums fills the ductal spaces and alveolar epithelium. 
After delivery, the circulating progesterone and estrogen levels fall, 
with increase in the level of prolactin which stimulates milk production 
and secretion. This is controlled by the neural reflex arc from the nerve 
endings of the nipple-areola complex. With menopause the estrogen and 
progesterone levels decrease causing involution of the ducts and alveoli, 
increase in the density of the fibrous tissue and fat.   
20 
 
INCIDENCE AND EPIDEMOLOGY 
Breast cancer is the major health problem for the women 
throughout the world. It accounts for 33% of all female cancers and 20% 
of cancer related deaths in women. Every year 9,00,000 new cases are 
diagnosed and causes approximately 3,76,000 deaths annually 
worldwide.  
In Chennai breast cancer accounts for 26.8% of all cancers in 
women. A few decades back breast carcinoma is more common in 
women above 50 years comprising about 65% to 70% with 30% to 35% 
of women were below 50 years of age. But at present the scenario has 
changed with increasing incidence below 50 years of age comprising of 
about 49%. Breast cancer scenario in India also shows a significant trend 
of increased incidence of breast cancer in much younger age than earlier. 
There is a sharp increase in the incidence of breast carcinoma due 
to the increased awareness and widespread use of screening 
mammography. However, mortality from breast carcinoma decreases due 
to early detection and multimodality treatment. 
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RISK FACTORS 
Multiple factors are associated with the increased risk of 
developing breast cancer. 
FAMILIAL FACTORS 
True hereditary predisposition exists in about 5% to 10% of the 
cases. The risk of developing breast cancer is 1.5 to threefold if the 
woman has first degree relative with breast cancer. 
GENETIC FACTORS 
Mutations in BRCA 1 and BRCA 2 gene is associated with 
increased risk of developing breast and ovarian carcinoma. It accounts for 
5% to 10% of breast carcinoma. It is inherited in autosomal dominant 
fashion.  
The histological features in BRCA 1 mutation has high incidence 
of medullary features and grade 3 tumours. In BRCA 2 mutations it is 
predominantly tubular and lobular variants. 
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HORMONAL FACTORS 
1. Increased exposure to endogenous estrogen – Early age at 
menarche, late menopause, nulliparity, delayed age at full term 
pregnancy increase the risk of breast carcinoma. 
2. Obesity and postmenopausal hormone replacement therapy 
increases the risk of breast carcinoma. 
DIETARY AND LIFESTYLE FACTORS 
 
1. Diet high in fat is associated with increased risk of breast 
carcinoma. 
2. Risk increases linearly with increased alcohol consumption. 
3. Decreased intake of vitamin c, beta carotene and folate is 
associated with increased risk. 
BENIGN BREAST DISEASE 
Proliferative breast disease with features of atypical hyperplasia is 
associated with increased risk of breast carcinoma. 
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ENVIRONMENTAL FACTORS 
Exposure to ionising radiation, electromagnetic fields, 
organochlorine pesticides at younger age before the age of 15 is 
associated with increased risk of breast carcinoma. 
ETIOLOGY AND PATHOGENESIS 
Breast carcinoma can be divided based on the risk factor into  
1. Sporadic breast carcinoma. 
2. Hereditary breast carcinoma. 
HEREDITARY BREAST CARCINOMA 
25% of familial cancers are due to mutation in the genes BRCA 1 
and BRCA 2, located in the chromosomes 17q21 and 13q12.3 
respectively. Both of them are tumour suppressor genes. Mutation in 
these genes results in uncontrolled proliferation of the breast epithelium 
resulting in breast carcinoma. BRCA 1  carcinoma has predominant 
histopathological characteristic of medullary carcinoma. BRCA 2 
tumours  does not have distinct morphological characteristic. 
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SPORADIC  BREAST CARCINOMA 
Sporadic breast carcinoma is associated with major risk factors 
related to early menarche, late menopause, duration of exposure to 
estrogens, exogenous exposure to estrogens. These carcinomas 
overexpress estrogen receptors. 
CLASSIFICATION OF PRIMARY BREAST CANCER 
NONINVASIVE EPITHELIAL CANCER 
1. Lobular carcinoma insitu (LCIS) 
2. Ductal carcinoma insitu or intraductal carcinoma.(DCIS) Papillary,  
cribriform, solid and comedeo types. 
 
 
 
 
 
 
 
 
 
A- LCIS 
B- DCIS solid type 
C- DCIS comedo type 
D- DCIS cribriform type 
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INVASIVE EPITHELIAL CANCER 
 Invasive lobular carcinoma 
 Invasive ductal carcinoma 
  Invasive ductal carcinoma, NOS 
  Tubular carcinoma 
  Mucinous or colloid carcinoma 
  Medullary carcinoma 
  Invasive cribriform carcinoma 
  Invasive papillary carcinoma 
  Adenoid cystic carcinoma 
  Metaplastic carcinoma 
MIXED CONNECTIVE AND EPITHELIAL TUMOURS 
 Phylloides tumours, benign and malignant 
 Carcinosarcoma 
 Angiosarcoma 
NOS, not otherwise specified. 
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MICROSCOPIC TYPES OF BREAST CARCINOMA 
NONINVASIVE BREAST CANCER 
Noninvasive breast cancers are lobular carcinoma in situ (LCIS) 
and ductal carcinoma in situ (DCIS).Lobular carcinoma in situ is 
considered as risk factor for breast cancer and is characterised by normal 
outline of the lobule , with expanded filled acini. Ductal carcinoma in situ 
is a heterogenous lesion with four types namely papillary, solid, 
cribriform and comedo. DCIS is characterised by discrete spaces with 
normal basement membrane filled with malignant cells surrounded by 
normal epithelial cells. Papillary and cribriform types are of lower grade. 
The solid and comedo types are high grade lesions. The malignant cells 
within the ductal membrane proliferate and undergoes central necrosis, 
because blood supply to these cells are outside the basement membrane. 
These necrotic debris undergoes calcification and can be detected in 
mammogram as segmental calcification. DCIS coexists with invasive 
cancers. 
INVASIVE BREAST CARCINOMA 
Tumours that are included in this group are those that exhibit 
stromal invasion. This include lobular carcinoma and ductal carcinoma. 
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INVASIVE DUCTAL CARCINOMA – NOS TYPE 
 
 
It accounts for 80% of breast cancers. It presents with microscopic 
or macroscopic lymph node metastases. Most  common in 
perimenopausal and postmenopausal women. According to WHO 
classification, invasive ductal carcinoma is most frequent and it should 
not fall into other types of invasive breast carcinoma. 
Microscopically to diagnose invasive ductal carcinoma NOS type, 
there should be a non specialised pattern in over 50% of tumour area. A 
pattern of trabecular, infiltrative margins, acinar, diffuse sheet like and 
nested patterns are noted. Hitologically they are graded into well 
differentiated, moderately differentiated and poorly differentiated based 
on pleomorphism, tubule formation and mitotic count. 
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Hormone receptor studies of invasive ductal carcinoma NOS type shows 
80% of ER/PR positivity and 30% of HER 2 neu positivity. 
INVASIVE LOBULAR CARCINOMA (ILC) 
 
 
The term infiltrating lobular carcinoma was introduced by Foot and 
Stewart. It accounts for 10% of breast carcinomas.  Microscopically it is 
composed of small cells with round nuclei, small amount of cytoplasm 
and inconspicuous nucleoli. Intracytoplasmic mucin displace the nucleus 
peripherally , signet-ring cell carcinoma. It is multicentric , multifocal 
and often bilateral.  
Receptor assay reveals ER/PR positivity in 62% to 90%, E-
Cadherin negativity and HER 2 neu negativity. 
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MUCINOUS CARCINOMA 
Mucinous carcinoma also called as colloid carcinoma , accounts 
for about 2% of all invasive beast carcinoma. More  common in elderly 
females. Presents as bulky tumour. Microscopically, it is characterised by 
the presence of extracellular pools of mucin surrounded by aggregates of 
low grade malignant cells. The cut surface of the tumour  shows 
glistening and gelatinous surface, with areas of fibrosis. The degree of 
fibrosis imparts a firm consistency to the tumour. About 66% of 
mucinous carcinomas exhibit hormone receptors. 33% of cases exhibit 
lymph node metastases. Survival rates at 5 and 10 years are 73% and 
59% respectively. Mucinous carcinoma shows HER 2/neu negativity. 
MEDULLARY CARCINOMA 
Medullary carcinoma is a high grade tumour. The tumour is a well 
circumscribed mass and it is soft in consistency. According to WHO 
medullary carcinoma is defined as a well circumscribed carcinoma 
composed of poorly differentiated cells with prominent lymphocytic 
infiltration and scant stroma. Inspite of high grade, it has a relatively 
good prognosis. 
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IHC studies shows negativity to estrogen expression and they exhibit 
immunophenotype  p53 positive and HER-2/neu negative. 
NEUROENDOCRINE CARCINOMA 
Nuroendocrine carcinoma was first described by Coombes RC in 
the year 1975. In the year 1977 Cubilla AL at al described in eight 
patients a new entity called primary carcinoid tumour. WHO defines 
neuroendocrine carcinoma when the tumour exhibits neuroendocrine 
marker  positivity  in  more  than  50%  of  the  tumour  cell  population.  It  
accounts for 10% to 18% of all invasive breast carcinoma. 
Microscopically it has infiltrative pattern composed of cells 
arranged in sheets, nests or trabecular formation with peripheral 
pallisading of cells. 
IHC shows 67% of the tumour exhibits estrogen positivity and 
56%  of the tumour exhibits progesterone positivity. HER-2/neu 
overexpression is negative in this type of carcinoma. 
PAPPILARY CARCINOMA 
It is a rare carcinoma in which invasive histopathological feature 
with predominant papillary structure is characteristic. 
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 IHC shows Estrogen receptor and progesterone receptor positivity and 
HER-2/neu negativity. 
CARCINOMA WITH METAPLASIA 
WHO   publication in the year 2003 defined metaplastic carcinoma 
as heterogenous   neoplasm composed of spindle cells, mesenchymal 
cells with mesenchymal differentiation. 
IHC studies  shows hormone receptors and HER-2/neu negativity 
and they are positive for keratin, EMA and S100. 
TUBULAR CARCINOMA 
It accounts for about 2% of the invasive breast carcinoma. It is 
more common in the perimenopausal and early menopausal age. 
Microscopically the cellular pattern are arranged in tubular pattern. 10% 
of the cases develop lymph node metastases and usually to the level I 
axillary group of lymph nodes. However the presence of distant 
metastases does not affect the survival. 
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PROGNOSTIC AND PREDICTIVE FACTORS FOR 
INVASIVE CARCINOMA 
Prognostic and predictive factors are grouped into tumour factors 
and host factors. 
Tumour factors include nodal status, tumour status, histologic 
grade, lymphovascular invasion, pathologic stage, hormone receptor 
status, DNA content, extensive intraductal component. 
Host factors include age, menopausal status, family history, 
previous breast cancer, immunosupression, nutrition, prior chemotherapy, 
prior radiation therapy. 
1. LYMPH NODE STATUS 
In invasive breast carcinoma axillary lymph node status is 
the most important prognostic factor. Macrometastases 
greater than 0.2 cm has an important prognostic significance. 
2. TUMOUR SIZE 
Tumour  size  which  is  an  important  component  of  TNM  
staging is an another important prognostic factor. It is 
independent of nodal status. 
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3. HISTOLOGIC GRADE 
The degree of tumour differentiation in invasive breast 
carcinoma is assessed using Bloom Richardson grading 
system. It includes tubule formation, nuclear grade and 
mitotic  rate.  Each element is  given a score of  1 to 3 with 1 
for best prognosis and 3 for the worst prognosis. 
Tubule formation 
 More than 75% of the tumour   1 
 10% to 75% of the tumour          2 
 <10% of the tumour                     3 
Mitotic count 
 0 to 9 mitoses/10 hpf                   1 
 10 to 19 mitoses/10 hpf               2 
 20 or > mitoses/10 hpf                 3 
Nuclear Pleomorphism 
 Small regular uniform cells          1 
34 
 
 Moderate nuclear size            2 
 Variation 
 Marked nuclear size variation 3 
COMBINED HISTOLOGIC GRADE 
 Low Grade I                                3-5 
 Intermediate Grade II                    6-7 
 High Grade III                                  8-9 
4. LYMPHOVASCULAR INVASION 
Tumour cells  may present within the lymphatics or within 
the capillaries surrounding the tumour. Presence of 
lymphovascular invasion is the strong predictor of survival 
outcome and is a poor prognostic indicator. 
5. PATHOLOGICAL STAGE 
The survival rate of women with special types of invasive 
carcinoma like mucinous, tubular, medullary, lobular and 
papillary is 60% when compared with women with cancers 
of no special type which is less than 20%. 
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6. ESTROGEN AND PROGESTERONE RECEPTORS 
Immunohistochemistry assays are used to study the hormone 
receptor status. Women with hormone receptor positive have better 
prognosis than hormone receptor negative. 
7. HER-2/neu 
HER-2/neu or human epidermal growth factor receptor 2 is a 
transmembrane glycoprotein. It’s main function is control of cell 
growth.  Overexpression of HER-2/neu is a bad prognostic factor. 
8. DNA CONTENT  
Those tumours with aneuploidy have abnormal DNA indices and 
are associated with bad prognosis. The amount of DNA present in 
each individual cell can be assessed by flow cytometric analysis. It 
can also be done by image analysis of tissue sections. 
9. MICROMETASTASIS 
In node negative breast cancer microscopic foci of tumour 
metastasis can be found in 9% to 13% of cases. The prognosis of 
patients with micrometastasis is (defined as less than 2 mm in 
diameter) same as that of in patients with node negative status. 
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10. TUMOUR ANGIOGENESIS 
Growth of new blood vessels adjacent to the tumour determines the 
risk of metastasis. More the number of blood vessels, more the risk 
of distant metastasis. 
IMMUNOHISTOCHEMISTRY 
Immunohistochemistry over the past two decades has evoloved 
into a revolutionary diagnostic tool in the practice of pathology. The 
identification of highly specific epitopes in paraffin wax embedded 
tissues with an antibody and labelling system is the procedure usually 
followed in cellular pathology. Immunohistochemistry is useful in a 
number of cases where morphology and clinical data alone are not 
sufficient for a firm diagnosis of the type of disease in tissue section. 
It was Francois VincentRaspard, botanist to first use 
immunohistochemistry. Immunohistochemistry  revolutionized by the 
advent of aniline dyes during the year 1862 to 1929. The technique we 
use today owe much to the diligent work done by some key researchers 
over the past sixty decades. In the year 1941, paper by Coons et al. has 
significant influences on the development of the fluorescent labelled 
antibody technique. 
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Later in the year 1966 the indirect technique was introduced by 
Nakane and Pierce, in that unlabelled antibody is followed by a second 
substrate or antibody. Immunohistochemistry developed through stages 
from peroxidase-antiperoxidase (1970), Labelling with Alkaline 
Phosphatase (1971), Avidin – biotin technique (1977, 1979) and to 
double layer dextrin polymer technique (1993) which carries both 
disadvantages and advantages for each techniques. 
DEFINITIONS 
IMMUNOHISTOCHEMISTRY 
It is a technique for identifying tissue or cellular constituents 
(antigen) by means of antigen – antibody interactions. The antibody site 
being identified either by use of a secondary labelling method or by direct 
labelling of the antibody. 
ANTIGENS 
An antigenic carbohydrate, protein or lipid molecule has one or 
more antibody binding sites. These regions composed of a small number 
of monosaccharide or aminoacid units and are known as antigenic 
determinant groups or epitopes. 
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ANTIBODIES 
Antibodies  are  a  class  of  serum  proteins  and  they  are  called  as  
immunoglobulins. They are formed in the humoral immune system after 
recognition  of  a  foreign  antigen  by  plasma  cells,  the  end  cell  of  B  cell  
transformation.  IgA,  IgD,  IgE,  IgG  and  IgM  are  the  five  types  of  
antibodies found in the blood. IgG is the most commonest antibody and is 
the most commonly used antibody in immunohistochemistry. 
DETECTION SYSTEM 
Two methods are employed for the detection of antigen – antibody 
reaction complex 
1. Direct method. 
2. Indirect method. 
DIRECT METHOD 
 
In this technique the primary antibody is conjugated directly to the 
label. Those which are labelled directly with a fluorochrome are the most 
popularly used direct conjugates. Horse radish peroxidase and alkaline 
phosphatase directly labelled antibodies are occasionally used. 
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ADVANTAGE 
1. Simple to use. 
2. Require one application of regeant, followed by application of 
the appropriate chromogen substrate. 
DISADVANTAGE 
1. Sensitivity is low 
2. Unable to detect small amounts of antigen that is essential for 
the diagnosis. 
INDIRECT METHOD 
This technique involves application of unconjugated primary 
antibody followed by the application of a labelled antibody. Horse radish 
peroxidase is the most commonly used label. It is a more sensitive 
technique, rapid and relatively less expensive. 
CURRENT TECHNIQUES 
A novel technique reported by Pluzek et al. in 1993 is an 
Enchanced polymer one step staining method (EPOS) which is a new 
direct technique. In this technique a large number of primary antibody 
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molecules along with peroxidase enzymes are attached to a dextran 
polymer “backbone”. This method is rapid, especially for frozen sections, 
able  to  detect  small  amount  of  antigen  present  in  the  tissue  and  
reproducibility present. 
A new indirect technique called as Dextran polymer conjugate 
Two – Step visualisation technique described by Dako A/S, is based on 
the dextran technology used in the EPOS system. It is less time 
consuming. 
ANTIGEN RETRIVAL IN IMMUNOHISTOCHEMISTRY 
The following technique can unmask antigen in routinely processed 
tissues. 
1. Proteolytic enzyme digestion 
2. Microwave antigen retrival. 
3. Pressure cooker antigen retrival 
4. Microwave and trypsin antigen retrival. 
 
 
41 
 
PROTEOLYTIC ENZYME DIGESTION 
Huang et al. (1976), Curran & Gregory (1977) and Mepham et al. 
(1976) described a technique of pre-treating formalin fixed paraffin 
sections with proteolytic enzymes to unmask the antigenic determinants. 
The most popular enzymes used are protease and trypsin. It is used for 
demonstrating immunoglobulins and complement in renal biopsies. It 
pitfalls include over digestion, antigen destruction and under digestion. 
MICROWAVE ANTIGEN RETRIVAL 
It involves boiling of dewaxed formalin fixed paraffin sections 
with a number of solutions and allows rapid and uniform heating. 
Proliferation markers such as anti-Ki67 and MIB1, which was previously 
used only on frozen sections, now can be used after heat pre-treatment on 
paraffin wax sections. 
PRESSURE COOKER ANTIGEN RETRIVAL 
Replacing the microwave oven with the pressure have showed to 
have some advantages by Norton et al. (1994). Microwave allows limited 
numbers, constant attention, time consuming and microwaving of large 
number of slides result in inconsistencies. But in pressure cooking 
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methods no such inconsistencies  are encountered and is less time 
consuming. 
MICROWAVE AND TRYPSIN ANTIGEN RETRIVAL 
Sandison et al. (1994) reported that a combination of microwave 
antigen retrival followed by trypsin digestion enables more reliable 
identification. Pitfalls include pre-treatment of the tissues by 
microwaving makes the tissue very sensitive to proteolytic enzyme 
digestion. 
USES OF IMMUNOHISTOCHEMISTRY IN BREAST 
PATHOLOGY 
1. Evaluation of estrogen and progesterone receptor status by using 
specific  antibodies to the estrogen and progesterone receptor 
proteins. 
2. Evaluation of HER-2/neu protein overexpression by using specific 
antibodies to the HER-2/neu receptor protein. 
3. Differentiating in situ carcinoma from invasive carcinoma by using 
antibodies to basement membrane proteins (type IV collagen, 
laminin) and to myoepithelial markers such as actins, calponin, 
smooth muscle myosin heavy chain. 
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4. Evaluation of metastatic lesions of possible origin from the breast 
by using antibodies to ER, GCDFP, CK 7/CK 20 and other 
markers. 
5. Assessment of spindle cell lesions (mesenchymal lesions vs 
metaplastic carcinoma). 
6. Differentiating lobular in situ carcinoma from ductal carcinoma in 
situ by using antibodies to E-cadherin. 
HORMONE RECEPTORS 
Elwood V.Jensen was the first person to identify the estrogen 
receptors in the year 1958, at the University of Chicago. Later in the year 
1996, the gene for the second estrogen receptor (ERß) was identified by 
Kupier et al. ER/PR receptors are nuclear receptors and are in about 7% 
of epithelial cells of the normal breast tissue. They are more abundant in 
the lobular cells than the ductal cells. 
Two  classes  of  estrogen  receptors  exists  namely  ER,  is  an  
intracellular receptor and GPER, a G protein coupled receptors. They are 
stimulated by the hormone 17ȕ estradiol.  Alpha and Beta are two 
different isoforms of estrogen receptors. Alpha receptor encoded by 
6p25.1 is found in breast cancer cells, endometrium and in ovarian 
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stromal cells and in males in efferent ducts. Beta receptor encoded by 14q 
is found in ovarian granulosa cells, kidney, brain, bone, heart, lungs, 
prostate and endothelial cells. Progesterone receptor is regulated by the 
estrogen receptor, thereby it is an indicator for intact ER functional 
pathway. 
Without stimulation the estrogen receptors are located in the 
cytosol. Only upon stimulation by the estrogen hormone the receptor 
migrate from the cytosol into the nucleus. Dimerization  of the receptor 
complex occurs and bind to the DNA. This DNA- receptor complex 
causes transcription of DNA to mRNA and activates MAPK/P13K 
pathway and causes change in cell function. Moreover estrogen is a 
steroid hormone and does not require a membrane bound receptors for 
them to bind with the estrogen receptor. 
Two hypotheses have been proposed for its tumourogenesis. One 
hypotheses states that the transcription activity is induced by the estrogen 
receptor by alternative RNA splicing of estrogen receptor alpha subunit 
thereby causing accumulation of genetic mutation and rapid uncontrolled 
proliferation. The other hypotheses states that tumourogenesis is due to 
accumulation of the toxic genomic wastes. 
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Hormone receptors helps in predicting the response to endocrine 
therapy and they are well established markers for carcinoma breast. 
Receptors can be assessed on either frozen section or on paraffin blocks 
by immunohistochemistry. Immunohistochemistry is found superior to 
Ligand Binding Assay (LBA). 
PROGESTERONE RECEPTOR 
It is an intracellular steroid receptor that binds to the hormone 
progesterone. It is controlled by the estrogen receptor and is encoded by 
the gene PGR 11q22. It is dependent in the estrogen functional pathway. 
Progesterone hormone stimulates the progesterone receptor by binding to 
it. Estrogen and progesterone receptor share a common functional and 
structural organisation. Expression of progesterone receptor is a 
predictive marker and PR positive breast carcinoma is ER positive also. 
Progesterone receptor was demonstrated by immunohistochemistry 
in formalin fixed paraffin section by Clarks et al. (1988).It is seen in the 
cells which are estrogen positive. Scoring system is also the same as for 
estrogen receptor. 
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SCORING SYSTEM 
Estrogen and Progesterone receptor express positivity to nuclear 
staining. They are read by the proportion of the tumour cells expressing 
positivity and the intensity of the reaction. Both are added to obtain a 
score. 
H – SCORE SYSTEM 
It is a semiquantitative assay and was proposed by Goulding et al 
(1995). It is based on the different degree of relativity as shown by 
tumour cells. A score of 0 – 3 was given. 
 0 – No reaction 
 1 – Weak reaction 
 2 – Moderate reaction 
 3 – Strong reaction 
Score calculation =  % weakly positive cells x 1 +  
    % moderately positive cells x 2 + 
    % strongly positive cells x 3 
Total score is between 0–300. Positive score is 51–300 and the negative 
score is upto 50 or less. The main disadvantage is time consuming and is 
impractical for the pathologists. 
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QUICK SCORE SYSTEM 
This score is based on the proportion of the stained cell and the 
intensity of the staining. It was proposed by Barnes et al.(1998). 
PROPORTION OF STAINING         INTENSITY OF STAINING 
0 = No nuclear staining                   0 =No staining 
1 = < 1% nuclei staining    1 = Weak staining 
2 = 1 – 10% nuclei staining   2 = Moderate staining 
3 = 10 – 33% nuclei staining   3 = Strong staining 
4 = 33 – 66% nuclei staining 
5 = 66 – 100% nuclei staining 
 
The total score is 8. When the score is more than 2 it is considered 
as positive. Advantage of the score is it predicts the probability of the 
response to hormone therapy 
 
Experience to date suggests that using a simple scoring system will 
predict the values for treatment. 
Score of 0 indicates that endocrine therapy will not work. 
Score of 2 – 3 indicates 20% chance of response to therapy. 
Score of 4 – 6 indicates 50% chance of response. 
Score of 7 – 8 indicates 75% chance of response. 
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Where progesterone receptors content has been determined, endocrine 
therapy is deemed worthwhile with low ER but high PR. 
 
HER-2/neu RECEPTORS 
 
HER-2 /neu or c-erb-2 is the second member of the type 1 tyrosine 
kinase family. It encodes a transmembrane glycoprotein that is 
overexpressed in tumour cells. This proto oncogene is encoded by 
17q11.2-q12. It belongs to EGFR family. Gene amplification is 
associated with poor prognosis. It can be detected by Florescent In Situ 
Hybridisation (FISH) and by immunohistochemistry for the protein 
overexpression. IHC is easy to perform and is cost effective than FISH. 
SCORING SYSTEM 
Staining pattern Score HER-2/neu expression 
No staining or 
membrane staining in 
<10% of cells 
 
A faint staining only a 
part of membrane 
>10% of cells 
           0 
 
 
 
 
 
           1 + 
 
 
 
 
 
 
Negative 
 
 
 
 
 
Negative 
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A weak to moderate 
complete staining in 
>10% of cells 
 
A strong complete 
membrane staining 
>10% of tumour cells 
 
           2 + 
 
 
 
 
 
 
 
           3 + 
 
Weakly positive 
 
 
 
 
 
 
 
Strongly positive 
 
ADVANTAGES OF ASSESSMENT OF ER / PR RECEPTORS IN 
BREAST CARCINOMA 
1. For tumour behaviour in breast carcinoma Estrogen and 
Progesterone receptors are strong predictive and weak prognostic 
factors. 
2. ER / PR positive tumours show response to hormone therapy in 50 
– 60% of cases. 
3. ER  /  PR  positive  tumours  are  associated  with  reduced  risk  of  
mortality and recurrence. 
4. ER / PR negative tumours show very poor response to endocrine 
therapy. 
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MATERIALS AND METHODS 
This is an analytical study done during the period from January 
2013 to October 2013. It is conducted to female patients presented with a 
breast lump in the female OPD, The department of General surgery, 
Govt. Stanley Hospital, Chennai. 
Female patients with palpable lump are admitted and are subjected 
to detailed history regarding age, parity, family history, socio economic 
status, menstrual history, lactational history and any previous biopsy 
reports if any. 
Newly diagnosed patients and with unilateral breast malignancies, 
with no history of neoadjuvant chemotherapy  are included in this study. 
Patients with bilateral breast malignancies and has a history of 
neoadjuvant chemotheroy are excluded from this study. 
Based on the clinical examination, patients are subjected to 
mammogram, fine needle aspiration cytology (FNAC). If FNAC is 
proven to be inconclusive, trucut biopsy was done. 
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Based on the results of triple assessment if proven to be malignant, 
staging work-up done with X-Ray chest, Ultrasonogram of abdomen and 
pelvis and Bone scan (locally advanced breast carcinoma). 
Based on the above findings patients are categorised as 
1. Early Breast carcinoma (T1, T2, N1, N0). 
2. Locally Advanced Breast Carcinoma (TxN2, T3Nx, T4Nx) 
In Early breast cancer patient is subjected to MRM. The specimen 
is sent for histopathological study and hormone receptor study. Based on 
the histopathological report and hormone receptor status, patient is 
followed up with adjuvant chemotherapy and radiotherapy. 
In Locally advanced breast carcinoma patient is subjected to trucut 
biopsy and the specimen is sent for histopathological study and hormone 
receptor status. 
Based on the report patient is started on neoadjuvant chemotherapy 
followed by MRM. Postoperatively patient is started with chemotherapy/ 
radiotherapy. 
Immunohistochemical analysis of hormone receptors are done in 
formalin fixed paraffin wax embedded tissue sections using the 
52 
 
Supersensitive Polymer HRP system which is based on non- biotin 
polymeric technology. It makes use of Super enhancer and poly HRP 
reagent. Then the retrieved antigen binds to primary antibody and then a 
secondary antibody conjugated with horse radish peroxidase polymer and 
DAB substrate is added for its detection. Then the score is calculated 
after required colour developed which can be read under a light 
microscope 
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OBSERVATION AND RESULTS 
TABLE 1. 
DISTRIBUTION OF BENIGN AND MALIGNANT BREAST 
TUMOURS. 
S.NO PERIOD 
BENIGN 
TUMOURS 
MALIGNANT 
TUMOURS 
1 Jan 2013 – Oct 2013 73 50 
 
TABLE 2. 
AGE WISE DISTRIBUTION OF THE TUMOURS 
S.NO 
AGE 
(IN YEARS) 
BENIGN                        
TUMOURS 
MALIGNANT 
TUMOURS 
1. Less than 20 Yrs 18 0 
2.      21 – 30 Yrs 35 3 
3.      31 – 40 Yrs 12 7 
4.      41 – 50 Yrs 7 21 
5.      51 – 60 Yrs 1 14 
6.      61 and above 0 5 
 Total No.of cases 73 50 
 
Table  2 shows the distribution of breast tumours according to age. 
Benign tumours had a peak incidence in the age group 21 – 30 years, 
where as the malignant tumours had a peak incidence in the age group of 
41 – 50 years. 
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TABLE 3.  
DISTRIBUTION OF HISTOLOGICAL VARIANTS IN BREAST 
CARCINOMA 
S.No. Histological variants No.of Cases Percentage 
1. Invasive Ductal Carcinoma – NOS 
type 
47 94% 
2. Invasive Lobular Carcinoma 2 4% 
3. Mucinous Carcinoma 1 2% 
 Total No.of Cases 50 100% 
 
Table  3 shows the distribution of histological variants in breast 
carcinoma. Among the 50 cases, 47 cases (94%) were Invasive Ductal 
Carcinoma Nos type, 2(4%) were Invasive Lobular carcinoma and 1 (2%) 
was Mucinous carcinoma. 
 
94%
4%2%
Chart 1. Distribution of Histological 
Variants Of Breast Carcinoma
Invasive Ductal Carcinoma – NOS type Invasive Lobular Carcinoma
Mucinous Carcinoma
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TABLE 4. 
DISTRIBUTION OF HISTOLOGICAL GRADE IN INVASIVE 
DUCTAL CARCINOMA - NOS TYPE. 
S.No. Histological Grade No.of Cases Percentage 
    1. Grade I 8 17% 
    2. Grade II 33 70% 
    3. Grade III 6 12% 
 Total No.of Cases 47 100% 
 
Table  4 shows the distribution of histological grading in breast 
carcinoma according to Modified Bloom Richardson scoring system. 
Only 47 cases were included for grading, in that 8 (17%) cases were in 
grade I , 33 cases (70%) were in Grade II, 6 cases (13%) were in Grade 
III. 
 
 
17%
70%
13%
Chart 2. Distribution of Histological Grade 
in IDC - NOS Type
Grade I Grade II Grade III
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TABLE 5. 
CORRELATION OF ESTROGEN RECEPTOR WITH 
PROGESTERONE RECEPTOR 
S.No Group No.of Cases Percentage 
   1.                    ER+/PR+             22            44% 
   2.                    ER-/PR+              9            18% 
   3.                    ER+/PR-              4             8% 
   4.                    ER-/PR-            15            30% 
           Total No.of Cases            50           100% 
 
Table 5. shows correlation of Estrogen receptors and Progesterone 
receptors. Among the 50 cases 22 cases were positive for both Estrogen 
and Progesterone receptors, 9 cases positive for progesterone receptor, 4 
cases positive for estrogen receptor, while 15 cases were negative for 
both estrogen and progesterone receptors. 
 
 
 
44%
18%
8%
30%
Chart 3. Correlation of Estrogen 
Receptor With Progesterone Receptor
ER+/PR+
ER-/PR+
ER+/PR-
ER-/PR-
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TABLE 6. 
EXPRESSION OF HER-2/neu IN BREAST CARCINOMA 
S.No HER-2/neu expression 
Total No. of 
cases 
Percentage 
   1.        Positive      18                
            50 
            36% 
   2.        Negative     32              64% 
 
Table 6. shows HER-2/neu overexpression in 50 cases of breast 
carcinoma, among them 18 cases (36%)  were found to be positive, while 
32 cases (64%) were found to be negative.  
` 
 
 
            
 
POSITIVE
36%
NEGATIVE
64%
Chart 4. Expression of HER-2/neu in Breast 
Carcinoma
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TABLE 7. 
CORRELATION OF TUMOUR SIZE WITH HORMONE 
RECEPTORS 
 
S.No 
Tumour Size Total 
ER/PR 
Positive 
Percentage 
   1.          T1 < 2 cm            7           6        85% 
   2.          T2  2 – 5 cm          17         16         94% 
   3.          T3  > 5 cm          26         13        50% 
    Total No.of Cases          50         35  
 
Table 7. shows correlation of hormone receptors with tumour size. 
Estrogen receptor and Progesterone receptor positivity was noted in 85% 
of  T1 sized tumours, 94% of T2 sized  tumours  and  50%  of  T3 sized 
tumours. The receptor status was found to be comparatively reduced in 
larger sized tumours as depicted. The correlation of hormone receptor 
with tumour size was statistically found to be significant (p=0.003). 
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Chart 5. 
CORRELATION OF TUMOUR SIZE WITH HORMONE 
RECEPTORS 
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TABLE 8. 
CORRELATION OF HER-2/neu WITH TUMOUR SIZE 
 
S.No. Tumour size 
 
HER-2/neu 
positive 
Total cases Percentage 
   1.        <2 cm 
 
            1         7       14% 
2.       2 – 5 cm 
 
            5       17       23% 
3.        > 5 cm 
 
           14       26       53% 
 
Table  8. shows correlation of HER-2/neu with tumour size. HER-2/neu 
overexpression was noted in 14% of T1 sized tumour, 23% in T2 sized 
tumour  and  53%  in  T3 sized tumour. HER-2/neu overexpression was 
found in increasing size of the tumour. 
Chart 6. 
CORRELATION OF HER-2/NEU EXPRESSION WITH TUMOUR 
SIZE 
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TABLE 9. 
CORRELATION OF RECEPTOR STATUS WITH 
HISTOLOGICAL GRADING 
 
S.No 
 
Histological 
grade 
Total No. 
of cases 
ER/PR 
Positive 
Percentage 
       1. 
 
       Grade I          8          8       100% 
      2. 
 
       Grade II         33        23         69% 
       Grade III           6          2         33% 
 
Table 9. shows correlation of hormone receptor status with tumour grade. 
Estrogen, Progesterone receptor positivity was seen in 100% in grade I 
tumours, 69% in grade II tumours and 33% in grade III tumours. This 
implies that high histological grade tumours showed low expression of 
receptor status.  
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CHART 7. 
CORRELATION OF RECEPTOR STATUS WITH 
HISTOLOGICAL GRADE 
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TABLE 10. 
CORRELATION OF HER-2/neu WITH HISTOLOGICAL 
GRADING 
 
S.No Histological grade HER-2/neu 
positive 
Percentage 
1. Grade I (8 cases) 0 0 
2. Grade II (33 cases) 11 33% 
3. Grade III (6 cases) 4 66% 
 
Table 10. shows correlation of HER-2/neu with histological grade. It was 
found that HER-2/neu overexpression was not seen in grade I tumours, 
where as it was expressed in 33% of grade II tumours and 66% of grade 
III tumours. Stastistically found to be significant (p=0.001). 
CHART 8. 
CORRELATION OF HER-2/neu WITH HISTOLOGICAL 
GRADING 
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TABLE 11. 
CORRELATION OF RECEPTOR STATUS WITH NODAL 
STATUS 
S.No Nodal metastasis ER/PR positive Percentage 
1. Present (17 cases) 9 52% 
2. Negative (29 cases) 21 72% 
 
Table 11. shows correlation of hormone receptors with nodal status. Out 
of 46 patients 17 had nodal metastasis, among whom 9 showed receptor 
positivity. Out of 29 nodal negative patients, receptor status was positive 
in 21 patients. This explains higher receptor expression in nodal negative 
patients. Statistically found to be significant (p=0.001). 
CHART 9. 
CORRELATION OF RECEPTOR STATUS WITH NODAL 
STATUS 
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TABLE 12. 
CORRELATION OF HER-2/neu WITH NODAL STATUS 
S.No Nodal metastases HER-2/neu positive Percentage 
1. Present (17 cases) 11 64% 
2. Negative (29 cases) 2 6% 
 
Table 12. shows correlation of HER-2/neu with nodal status. Out of 46 
cases, HER-2/neu overexpression was seen in 64% of nodal positive 
patients as opposed to 6% of nodal negative patients. Statistically found 
to be significant (p=0.001).  
CHART 10. 
CORRELATION OF HER-2/neu WITH NODAL STATUS 
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TABLE 13. 
CORRELATION OF RECEPTORS WITH ONCOPROTEIN 
EXPRESSION 
ER/PR Status HER-2/neu 
Positive Negative 
Total No. of cases 
Positive 9                  26 35 
Negative 9 6 15 
Total No. of cases 18 32 50 
 
Table 13. shows an inverse relationship of estrogen, Progesterone 
receptor status with the HER-2/neu status. 
Statistical analysis was performed and found to significant (p=0.001). 
CHART 11. 
CORRELATION OF RECEPTORS WITH ONCOPROTEIN 
EXPRESSION 
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DISCUSSION 
INCIDENCE AND AGE OF OCCURRENCE: 
In  Indian  scenario,  breast  carcinoma  accounts  for  33%  of  all  
female cancers and 20% of cancer related deaths in women. In Chennai 
breast cancer accounts for 26.8% of all cancers in women. A few decades 
back breast carcinoma is more common in women above 50 years 
comprising about 65% to 70% with 30% to 35% of women were below 
50 years of age. But at present the scenario has changed with increasing 
incidence between 41- 50 years of age comprising of about 49%. Breast 
cancer scenario in India also shows a significant trend of increased 
incidence of breast cancer in much younger age than earlier. 
In accordance with the above mentioned studies, the present study 
also revealed that the distribution of the disease has a peak age 
occurrence of 41 – 50 years age group. 
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TABLE 14. 
COMPARATIVE ANALYSIS OF DISTRIBUTION OF 
HISTOLOGICAL VARIANTS OF BREAST CARCINOMA 
 
Histological 
Types 
Dixon JM et al. Omar Hameed Current study 
IDC – NOS type 79% >70% >70% 
Lobular 
carcinoma 
10% 5 – 15% 4% 
Mucinous 
carcinoma 
2% 1 – 5% 2% 
Medullary 
carcinoma 
2% 1 – 7% 0 
Papillary 
carcinoma 
1% 2% 0 
Solid 
neuroendocrine  
<1% Rare 0 
Metaplastic ca 0 2-5% 0 
 
Table14. shows  the  comparative  analysis  of  the  distribution  of  
histological variants of breast carcinoma. The incidence encountered by 
Dixon et al and Omar Hameed et al. were comparable with the present 
study. The most common histological type in concurrence  with the other 
results was Invasive ductal carcinoma – NOS type. 
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 THE IDENTIFIABLE HISTOLOGICAL VARIANTS ARE AS 
FOLLOWS 
1. INVASIVE DUCTAL CARCINOMA –NOS TYPE:  
This is the largest group of malignant tumours accounting to 65-
80% of breast carcinoma . Our study shows 94% distribution. Grossly the 
tumour size varied from 2cm to 12 cm. Cut section of most of the tumour 
showed gray white, ill-defined tumour mass, firm to hard in consistency. 
Occasionally  tumour showed areas of hemorrhage and necrosis. 
Microscopically the neoplastic cells were arranged in diffuse sheets,nests 
and cords along with glandular and tubular differentiation. In few cases 
comedo - pattern of necrosis was seen. About 40 percent of the cases 
(17/43) showed nodal metastasis. Most of the tumours were found to be 
in histological grade II. Resected margin involvement was seen in two 
patients and was confirmed by microscopic examination.  
2. INVASIVE LOBULAR CARCINOMA: 
An incidence of 4.9 -12% in post menopausal age group was 
recorded by Foot and Stewart. In the present study this variant 
represented 4% of occurrence. The peak age of occurrence is 41 - 45 
years. Grossly the tumour was gray white, firm measuring 6cms in 
diameter. Microscopically “Indian file” pattern was noted. The cells were 
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small to medium sized with uniform, hyperchromatic nuclei, and mild 
nuclear pleomorphism. Microscopically, metastasis was found in 23 
lymph nodes.  
3. MUCINOUS CARCINOMA: 
In Omar Hameed et al study incidence of Mucinous carcinomas 
was 5-15% and the mean age of occurrence was 58-68 years. The present 
study  data  represents  2%  of  distribution  and  the  age  of  occurrence  was  
73years. This is parallel with above mentioned study. Grossly the tumour 
mass was about 6cm -10cm, well circumscribed with gelatinous 
appearance. On cut section soft, gel like material was noted. 
Microscopically clusters of bland appearing epithelial cells with abundant 
extracellular mucin were noted . 
 
HORMONE RECEPTOR STATUS AND HER-2/NEU IN BREAST  
CARCINOMAS 
Estrogen, Progesterone receptor positive tumours have a 
significantly longer disease free survival than with the receptor negative 
tumours.  In  1975  Rosen  et  al.  attempted  to  correlate  Estrogen,  
Progesterone  receptors  status  along   with  various  histological  types  of  
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breast carcinoma. In his study Estrogen, Progesterone receptors were 
positive in 70-80% of the tumours and HER-2/ neu expression was 
positive in 15-20% of the breast carcinoma specimen. 
In the year 1993, Wilbur D et al.  did a study about hormone 
receptor status in 30 patients by immunohistochemical method on 
paraffin wax  embedded blocks. He described Estrogen receptors 
positivity in 73% (22/30) of patients, Progesterone receptors positivity in 
63% (19/30) of patients, and HER-2/neu overexpression in 37% (11/30) 
of patients. 
In the year 2003 Lici et al. have reported about the incidence of 
invasive carcinoma by hormone receptor status from the year  1992 to 
1998, in a population based study. He found that there is a increase in 
prevalence over the years with increase in hormone receptor positivity 
from 75.4% to 77.5% in United States.  
The number of studies performed on the hormone receptor status is 
much less in Asian women when compared with western world. In the 
year 2000  Desai et al. documented the Estrogen, Progesterone receptors 
status of carcinoma breast in India. The study was done with the help of 
immunohistochemical  method. He studied a total of 798 tumours, in that  
72 
 
32.6% were Estrogen receptor positive and  Progesterone receptor 
positive were 46.1%. He reported a high incidence of hormone  receptors 
non-reactivity in breast carcinoma patients in India. 
In the year 2008 , Col.V. Dutta et al. did a study in Armed Forces 
Medical College, Pune.  He analyzed the hormone receptors and HER-
2/neu  overexpression  in  breast  carcinoma.  In  total  of  75  tumours  which  
was studied, 33% (25/75) of cases expressed Estrogen receptor positivity, 
Progesterone receptor or both where  found to be negative in as 67% 
(50/75). HER-2/neu overexpression was seen in 58 %( 43/75) of cases. 
This study revealed that receptor negativity is higher in this population of 
tumours when compared with the western communities. 
In the year 2009, Lakmini K.B Mudduwa  studied the hormone  
receptor status of breast carcinoma by using the Quick score method. She 
reviewed a total of 151 cases and documented the prevalence of Estrogen 
receptor positivity in 45.7% of the cases, Progesterone receptor positivity 
in 48.3% of the cases and both receptors negativity in 54.3% of the total 
cases. According to her study HER-2/neu overexpression was seen in 
19.1% (26/136) of the total cases. 
In  the  year  2009,Tanuja  Shet  et  al.  did  a  study  on  the  hormone  
receptors expression in the last 8 years from the year 1999 to 2006 in a 
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cancer referral institute in India. A total of 11,780 cases were reviewed 
for this period. The percentage of hormone receptor positive expression 
varied from 52% to 57%. 
In  the  year  2007,  Vikash  Kumar  et  al.  did  a  study  on  HER-2/neu  
overexpression which has a much higher incidence among Indian breast 
cancer patients which is  46.3% in comparison to 25-30% in Western 
world. 
In the present  study Estrogen,  Progesterone receptor or  both were 
positive in 70% of cases and both receptors were negative in 30% of 
cases (Tab.5).  
HER-2/neu overexpression was positive in 36% of cases (Tab.6). 
Hence this study is comparable with the studies conducted in the Asian 
communities. There appears to be a minimal variation in receptor 
expression;because technically this could be explained by the differences 
in the technique of evaluation and inter laboratory variations. 
ESTROGEN, PROGESTERONE RECEPTOR AND HER-2/NEU 
STATUS IN HISTOLOGICAL VARIANTS 
In the year 1975, Rosen PP et al. found that Mucinous carcinomas, 
Papillary carcinomas are Estrogen and Progesterone receptors positive 
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whereas Medullary carcinoma and Metaplastic carcinoma were both 
found to be hormone receptor negative. He has also found that a small 
group of Invasive ductal carcinoma-NOS type and Lobular carcinomas 
expressed receptor negativity. 
In the year 2000, Desai et al. reported that Invasive lobular 
carcinoma, Mucinous carcinoma and mixed tumours were Estrogen and 
Progesterone receptor positive, where as high grade infiltrating ductal 
carcinomas, in situ comedo-ductal carcinomas ,Medullary carcinomas 
were found to be receptor negative. 
The author Diab SG et al did a study on the tumour characteristics 
and clinical outcome of Mucinous and Tubular breast carcinomas and 
found Estrogen receptor positivity in 92%  of cases and reported 
Progesterone receptor positivity in 68% of cases. HER-2/neu 
overexpression is found to be less than 5% of tumours. Similar results 
were also reported in studies conducted by Shousha S, et al. in the year 
1989. 
In the year1988, Reiner et al. found that Papillary carcinomas 
expressed 100% Estrogen receptor positivityand expressed 80% of 
Progesterone receptor positivity. They tend to have a HER-2/neu 
negativity . 
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In the year 1995, Rosen et al. did a study on HER-2/neu expression 
in nodal negative patients. He has also reported low incidence of 
oncogene expression in Papillary carcinomas. 
In  the  year  1991,  Soomro  S  et  al.  did  a  study  about  oncogene  
expression in different histological variants of invasive breast carcinomas 
and reported low expression in Neuroendocrine carcinomas. 
Immunohistochemical studies done by LeeAK revealed 
Neuroendocrine marker positivity in 82% of the cases. However 67%  
expressed Estrogen receptor positivity and 56% showed Progesterone 
receptor positivity. However ,HER-2/neu over expression was found to 
be negative. 
The present study also shows Estrogen and Progesterone receptor 
positivity and HER-2/neu expression negativity. This is in correlation 
with the above mentioned studies. 
In the year 1987, Oberman HA et al. did a study which showed that 
Metaplastic carcinomas were hormone receptor and oncoprotein negative 
called as Triple negative. 
In  the  year  1986,  Horsfall  et  al.  conducted  a  study  on  the  
relationship between DNA ploidy and steroid receptors. He found that 
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Medullary carcinoma has a higher  nuclear grade  with receptor 
negativity. 
In the year 1995, a study conducted by Rosen PP et al. and Soomro 
S.et al. in the year 1991  showed a low incidence of HER-2/neu  
overexpression in Metaplastic and Medullary carcinoma. 
In the year 1992,Kuenen–Boumeester V et al did a study on the  
immunohistochemistry of Androgen receptors in relation to the Estrogen 
and Progesterone receptors. He also reported that a small group of lobular 
carcinomas were found to express both receptors negativity and 
Androgen receptor positivity. 
In  the  year  1995,  a  study  conducted  by  Rosen  PP  et  al.  showed  
Estrogen receptor positivity in 87.55%  of the cases and Progesterone 
receptor positivity in 75% of the cases in Invasive lobular carcinomas. A 
small group of these tumours also expressed both receptor negativity and 
Androgen receptor positivity. 
In the year 2005, Riva et al studied about the 
immunhistochemical analysisof Androgen receptor in carcinoma breast 
and reported increased  frequency  of  androgen  receptor expression in  
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Lobular carcinomas along with Estrogen and Progesterone receptors 
negativity. 
In correlation with the above mentioned studies the Invasive 
lobular carcinoma in the current study also expressed both receptors and 
HER-2/neu negativity. Clinicopathologically this can be explained by the 
aggressive nature of the tumour with higher incidence of nodal 
metastases. 
ER POSITIVE 
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CORRELATION OF AGE AND RECEPTORS EXPRESSION 
TABLE 15. 
CORRELATION OF AGE AND RECEPTORS EXPRESSION. 
Age group( years ) Total No. of cases ER/PR positive 
31 – 40 7 3 
41 -50 21 14 
51 – 60 14 11 
60 and > 5 4 
 
In  the  year  2008,  Col.V.  Dutta  et  al.  studied  about  the  Estrogen,  
Progesterone receptor expression with the age. Out of the total  75 cases, 
35% of cases were in 51-60 years age group. The results showed that  the 
receptor positivity increases with advancing age. Young patients tend to 
have a higher level of circulating estrogen and hence correspondingly low 
expression of receptors. 
In the year 2005, Nidal M Almasri et al. reviewed about 91 
specimens of breast carcinoma during the period of 1995-1999. He has 
found significant receptor expression in 58% patients older than 50 years. 
80 
 
The present study shows receptor status positivity of 78%  in 
patients older than 50years  of age group. The Increased 
immunoreactivity with advancing age is parallel to above the mentioned 
studies. 
ESTROGEN, PROGESTERONE RECEPTOR, HER-2/NEU WITH 
OTHER VARIABLES 
In the year 1995, Rosen PP et al. in his study correlated Estrogen, 
Progesterone receptor positivity with histological grade and tumour size. 
He concluded that Estrogen and Progesterone receptors are expressed 
more in the low grade and tumours which are of lesser diameter. He also 
reported that HER-2/ neu overexpression was increased among the nodal 
positive patients and tumours  which are more than 2cm in diameter. 
J.Buon et al. reported that HER-2/neu receptor overexpression is 
increased in higher grade tumours. Hormone receptor positivity was seen 
100% in grade I tumours, 76.30% in grade II tumours and 41.18% in 
grade III tumours. Their receptor positivity tends to have an inverse 
relationship with the tumour grade. 
In the year 2008, S.Goyle et al. conducted a retrospective study in 
India. He reviewed about 131 patients and found that the hormone 
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receptor and oncoprotein expression does not necessarily correlate with 
advanced  grade tumours in our population. 
In  contrast  with  S.Goyle  et  al.  in  the  year  2008  the  present  study  
showed the Estrogen, Progesterone receptor positivity of 100% in grade I, 
69% in grade II, 33% in grade III tumours. HER-2 /neu overexpression 
showed 66% in grade III, 33% in grade II, none in grade I tumours. This 
explains the overexpression of oncoprotein with higher histological grade 
tumours. Thus, it reflected a direct relationship with higher nuclear grade, 
which was comparable with J.Buon et al  & Rosen PP et. 
Current study shows correlation of hormone receptors and HER-
2/neu with tumour size.The tumours are categorized into three according 
to T in TNM staging. T1- < 2cm, T2=2-5cm, T3 = > 5 cm. Receptor 
positivity is expressed in 85% of T1, 94% of T2 and 50% of T3 tumours. 
This explains that receptor positivity has an inverse relationship with the 
tumour size. 
HER-2/neu overexpression showed positivity in 14% of T1,23% in 
T2 and 59% in T3 tumours. This explains the higher expression of 
oncoprotein among the tumours of more than 2 cm size. 
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CORRELATION WITH NODAL STATUS 
In the year 2008, Col.V. Dutta et al. expressed a strong correlation 
between HER-2/neu and nodal metastases. He reported that 70% of nodal 
positive tumors  overexpressed HER-2/neu oncoprotein. 
H.J.  Huang et  al.  did a study in 1362 women with primary breast  
tumour. He found that Estrogen receptor positivity was expressed less in 
nodal positive tumours. 
In the present study out of 46 patients 17 cases showed metastasis 
while 29 cases has no metastases. Receptor positivity was found to be 
higher among the nodal metastasis negative patients which was about 
72% (21/29).HER-2/neu overexpression was seen in 64% of nodal 
positive cases than the nodal negative patients which was found to  
be 6 %. 
CORRELATION OF ESTROGEN, PROGESTERONE 
RECEPTOR WITH HER-2/NEU 
H.J.  Huang et  al.  conducted a study in 1362 women with primary 
breast tumours. He has found an inverse relationship with hormone 
receptor and oncoprotein expression. This can be explained by the fact 
that there is cross-linkage between the two pathways of tumour growth. 
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The present study  showed an inverse relationship between these 
hormone receptors and oncoprotein expression.Hence it is comparable 
with the above  mentioned studies. 
In the year 2006,  Francis  G et  al.  did a study of 591 tumours and 
concluded that more than 20% of HER-2/neu positive tumours showed 
moderate or strong staining for Estrogen receptors. 
In the year 2009, Bhargava R et al. has reviewed about 205 cases 
and concluded that 15% (32/205) of the cases were triple negative, 4% 
(8/205) of cases were positive for Estrogen receptor and HER-2/neu 
hybrid oncoprotein expression. 
In correlation with the above mentioned studies the present study 
also showed a inverse relationship with hormone receptor and 
oncoprotein expression. 
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SUMMARY AND CONCLUSION 
x The benign lesions had a peak occurrence in the age group 21 to 30 
years, whereas malignant tumours had a peak in the age group 41 
to 50 years. 
x Among the various histological variants in breast carcinoma, 
Invasive  Ductal  carcinoma  –  NOS  type  constituted  about  94%  of  
cases. 
x Estrogen, Progesterone receptor positivity and HER-2/neu 
negativity in Mucinous carcinomas. 
x Triple negativity in small group of Invasive lobular carcinoma. 
x Regarding the histological grade of breast carcinoma, Grade II 
tumours were common accounting for 70 %. 
x Estrogen and Progesterone receptor or both was found in 70% 
while 30% were found to be receptor negative. 
x HER-2 /neu overexpression was found to be positive in 36% of 
tumours and it was negative in 64% of tumours. 
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x Out of the total 50 cases, 26 cases were T3 tumours of more than 
5cms in diameter. 
x Larger the tumour size lesser is the expression of hormone 
receptor, whereas smaller sized tumours expressed more receptor 
positivity. This inverse correlation was statistically significant 
(P=0.003). HER-2/neu overexpression was found in tumours of 
more than 2 cm in size.  
x Among the 46 cases, nodal metastasis were found in 17 cases and 
negative in 29 cases. 
x Among the 29 nodal negative patients Estrogen, Progesterone 
receptor were positive in 21 cases. Thus, there is higher receptor 
expression in nodal negative patients. This was found to have a 
significant correlation (P=0.001). 
x HER-2/neu overexpression was observed in 64% of nodal positive 
patients, which is statistically significant (P=0.001). 
x Higher the histological grade of breast carcinoma, lower the 
receptor positivity. 33% of the grade III tumours expressed 
receptor positivity in comparison to 100% in grade I tumours. 
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x Higher the histological grade of breast carcinoma, greater the 
HER-2/neu overexpression, which was found to have a significant 
correlation (P=0.001). 
x Higher the Estrogen, Progesterone receptor positivity, lower was 
the HER-2/neu overexpression. Thus, there was an inverse relation 
between the receptor and HER-2/neu, which was found to be 
statistically significant (P=0.001). 
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CONCLUSION 
Estrogen, Progesterone receptor positive tumours are more 
common in the post menopausal women, tumours of more than 2cm in 
size, Histological grade I and in nodal negative patients. Oncoprotein  
overexpression is common among the tumours of more than 2cm in size, 
grade III tumours and in nodal positive patients. Hormone receptor and 
oncoprotein expression has an inverse correlation with each other. 
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PROFORMA
• NAME : SL. NO:
• AGE /SEX:
• ADDRESS WITH CONTACT NUMBER:
• IP NO:
• DATE OF ADMISSION:
• DATE OF SURGERY:
HISTORY OF PRESENTING ILLNESS:
Lump
- Duration
- Onset
- Rate of  growth
Pain
- Character and features of pain
- Relation to menstruation
Discharge from nipple
- Duration
- Quality- nature, color, odour.
- Quantity.
Retraction of nipple
H/o of trauma
H/o loss of weight/appetite
H/o of bone pain
H/o of jaundice
H/o of breathlessness
H/o of cough with hemoptysis.
PAST HISTORY :
H/o DM, HT,TB,Asthma,epilepsy.
H/o any previous surgery
H/o of drugs/ oral contraceptives.
FAMILY HISTORY:
Family history of Breast carcinoma, ovarian tumors, uterine tumors.
PERSONAL HISTORY:
Age at menarche, childbirth.
Marital status
Breastfeeding
Age at Menopause.
TREATMENT HISTORY:
SYSTEMIC EXAMINATION:
CVS
RS
PER ABDOMEN
CNS
EXAMINATION OF BREAST
INSPECTION
1.Inspection of the patient in sitting posture, arms by the side of her body
- Breast
- Skin over the Breast
- Nipple
- Areola
- Arms and Thorax
- Axilla
- Supraclavicular fossa
2. Inspection of the patient with arms raised above head
- Peau de orange present/absent.
- Fixity present/absent
- Retraction of nipple
3. Inspection on leaning forward
- Fixity to chest wall
4.Inspection on contracting and relaxing pectoralis major.
- Swelling becomes prominent or not
PALPATION
1.Local temperature and tenderness.
2.Swelling
3.Fixity to skin
4.Intrinsic mobility.
5.Fixity to chestwall
6.Fixity to muscles.
EXAMINATION OF AXILLARY LYMPHNODES
Examination of other Breast,opposite axilla, supraclavicular fossa.
PR/PV.
DIAGNOSIS:
INVESTIGATIONS
CBC
RFT
LFT
X-RAY chest
ECG
USG/ Mammogram
FNAC
Trucut Biopsy
IHC- ER,PR,HER 2/neu
SURGERY DONE:
HPE REPORT
MASTER CHART
S.
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(c
m
)
1 CHINNAMMAL 8276 75 416/13 542 Rt MRM T4bN0M0 12*10*3
2 RAMZAN BEE 7412 53 495/13 598 Lt MRM T2N0M0 3*3*2
3 CHANDRA 7812 46 514/13 613 Rt MRM T2N0M0 2.5* 2* 2
4 VICTORIA 1936 50 649/13 217 Lt MRM T4bN0M0 8*5*4
5 KALAISELVI 4357 56 739/13 289 Lt MRM T3N0M0 6*4*2
6 KUMARI 2452 76 766/13 227 Lt MRM T1NOMO 2*2*1
7 OMANA 3910 61 666/13 509 Rt MRM T1N0M0 2*2*1
8 KAMATCHI 7382 56 1050/13 865 Rt TRUCUT T4BN0M0 6*5*3
9 SHAMIRA 8787 40 1119/13 466 Lt TRUCUT T4BN0M0 7*5*3
10 VIJALAKSHMI 8826 26 1128/13 897 Lt TRUCUT T3N1M0 6*5*3
11 KALA 7152 35 1202/13 789 Rt MRM T3 N0M0 6*4*3
12 LALITHA 6573 50 1338/13 801 Rt MRM T2N1M0 3*2*2
13 RAVANAMMA 12149 41 1608/13 946 Lt  TRUCUT T3N1M0 6*5*4
14 NAGAMMAL 11823 55 1818/13 1012 Lt MRM T1N2M0 2*2*1
15 SAKKAMMA 11487 60 1887/13 1021 Rt MRM T2N0M0 3*3*2
16 YASODHA 12511 54 1934/13 1212 Lt MRM T2N0M0 4*3*2
17 VIJAYA 14282 35 1935/13 1232 Lt MRM T3N0M0 6*5*3
18 KANAGA 21483 45 2796/13 1453 Lt MRM T2N0M0 4*3*3
19 RADHA 22400 60 2822/13 2040 Lt MRM T4bN1M0 5*4*3
20 GNANASELVAM 23145 56 2839/13 2105 Rt MRM T3N1M0 5*4*4
21 PREMA 24057 53 2871/13 2112 Rt MRM T2N1M0 4*3*2
22 FATHIMA 24518 48 2917/13 2219 Lt MRM T3N1M0 6*5*4
23 MOHANA 25178 35 3131/13 2561 Lt MRM T4bN1M0 7*4*3
24 PARIMALA 25217 53 3212/13 2781 Rt MRM T3N1M0 6*5*4
25 KAVYA 26711 39 3617/13 2889 Lt MRM T1N0M0 2*2*2
26 MALATHY 29010 44 3913/13 3131 Rt MRM T3N1M0 7*5*4
27 BANU 31145 51 4131/13 3211 Lt MRM T3N0M0 6*5*3
28 LAVANYA 32121 44 4191/13 3231 Lt MRM T2N0M0 4*4*3
29 MARIAMMAL 32213 43 4277/13 3421 Rt MRM T4bN1M0 7*6*4
30 TAMILSELVI 33415 58 4532/13 3796 Lt MRM T3N1M0 6*4*3
31 KALAIARASI 35167 62 4632/13 3981 Rt MRM T3N0M0 6*5*4
32 SELVI 37182 70 4976/13 4321 Lt MRM T4bN1M0 5*4*3
33 MAHAMAYI 39876 64 5321/13 4543 Lt MRM T3N1M0 6*5*3
34 JHANSI 41121 57 5543/13 4873 Rt MRM T2N1M0 3*3*2
35 VANI 42311 48 5764/13 4976 Lt MRM T2N1M0 3*3*2
36 MAHIMAI 44321 51 5871/13 5141 Rt MRM T2N0M0 4*3*2
37 SADHANA 46431 49 6016/13 5211 Lt MRM T3N1M0 7*6*5
38 REVATHY 47811 42 6143/13 5321 Lt MRM T2N0M0 4*3*3
39 VASUMATHI 48765 44 6321/13 5331 Lt MRM T3N0M0 5*4*3
40 VAIDHEGI 49012 49 6487/13 5432 Rt MRM T1N0M0 2*2*1
41 REKHA 49812 29 6496/13 5561 Rt MRM T1N0M0 2*2*1
42 KUMARI 50121 35 6675/13 5613 Lt MRM T2N0M0 4*3*2
43 NALINI 51212 39 6875/13 5813 Rt MRM T3N1M0 6*5*3
44 MEGALA 52312 47 6945/13 5913 Lt MRM T2N1M0 4*3*2
44 MANIAMMA 53124 46 7076/13 6134 Rt MRM T3N1M0 6*5*4
45 KUPPAMAL 54121 53 7132/13 6321 Rt MRM T4bN1M0 5*4*3
46 NALINI 55132 55 7564/13 6453 Rt MRM T2N0M0 4*3*2
47 PAPPATHY 56432 29 7613/13 6543 Lt MRM T2N0M0 3*2*1
48 PARIMALAM 57543 38 7765/13 6654 Rt MRM T3N0M0 6*4*3
49 SAROJA 58431 45 7865/13 6754 Lt MRM T2N1M0 6*5*3
50 BEGUM 59546 49 7998/13 6854 Rt MRM T1N0M0 2*2*1
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1 CHINNAMMAL 75 IDC-NOS II + - + + + T4bN0M0 12*10*3
2 RAMZAN BEE 53 IDC-NOS II - - + + - T2N0M0 3*3*2
3 CHANDRA 46 IDC-NOS II + - + + + T2N0M0 2.5* 2* 2
4 VICTORIA 50 IDC-NOS II + - + - + T4bN0M0 8*5*4
5 KALAISELVI 56 IDC-NOS II - - + + - T3N0M0 6*4*2
6 KUMARI 76 MUCINOUS - - + + - T1NOMO 2*2*1
7 OMANA 61 IDC-NOS I - - - + - T1N0M0 2*2*1
8 KAMATCHI 56 IDC-NOS II NA - + + T4BN0M0 6*5*3
9 SHAMIRA 40 IDC-NOS II NA + + + T4BN0M0 7*5*3
10 VIJALAKSHMI 26 IDC-NOS II NA + + - T3N1M0 6*5*3
11 KALA 35 IDC-NOS II - - - + - T3 N0M0 6*4*3
12 LALITHA 50 IDC-NOS III + - + + + T2N1M0 3*2*2
13 RAVANAMMA 41 ILC + NA + + - T3N1M0 6*5*4
14 NAGAMMAL 55 IDC-NOS II - - - + - T1N0M0 2*2*1
15 SAKKAMMA 60 IDC-NOS II - - + + - T2N0M0 3*3*2
16 YASODHA 54 IDC-NOS II - - + + - T2N0M0 4*3*2
17 VIJAYA 35 IDC-NOS II + - - - + T3N0M0 6*5*3
18 KANAGA 45 IDC-NOS II - - - + - T2N0M0 4*3*3
19 RADHA 60 IDC-NOS II + + - + + T4bN1M0 5*4*3
20 GNANASELVAM 56 IDC-NOS I + - + + - T3N1M0 5*4*4
21 PREMA 53 IDC-NOS II + - + + - T2N1M0 4*3*2
22 FATHIMA 48 IDC-NOS III + - + + + T3N1M0 6*5*4
23 MOHANA 35 IDC-NOS II + - - - + T4bN1M0 7*4*3
24 PARIMALA 53 IDC-NOS II + - + + - T3N1M0 6*5*4
25  KAVYA 39 IDC-NOS II - - - - + T1N0M0 2*2*2
26 MALATHY 44 IDC-NOS III - - - - + T3N1M0 7*5*4
27 BANU 51 IDC-NOS II - - + + - T3N0M0 6*5*3
28 LAVANYA 44 IDC-NOS I - - + + + T2N0M0 4*4*3
29 MARIAMMAL 43 IDC-NOS II + - + + - T4bN1M0 7*6*4
30 TAMILSELVI 58 IDC-NOS II - - + + + T3N1M0 6*4*3
31 KALAIARASI 62 IDC-NOS II - - + - - T3N0M0 6*5*4
32 SELVI 70 IDC-NOS III + + - - + T4bN1M0 5*4*3
33 MAHAMAYI 64 IDC-NOS II - - + + + T3N1M0 6*5*3
34 JHANSI 57 IDC-NOS II - - + + + T2N1M0 3*3*2
35 VANI 48 IDC-NOS II - - + + - T2N1M0 3*3*2
36 MAHIMAI 51 IDC-NOS I - - + + - T2N0M0 4*3*2
37 SADHANA 49 IDC-NOS III + - - - + T3N1M0 7*6*5
38 REVATHY 42 IDC-NOS I - - + + - T2N0M0 4*3*3
39 VASUMATHI 44 IDC-NOS II - - + + - T3N0M0 5*4*3
40 VAIDHEGI 49 ILC - - - - - T1N0M0 2*2*1
41 REKHA 29 IDC-NOS I - - + + - T1N0M0 2*2*1
42 KUMARI 35 IDC-NOS II - - + - - T2N0M0 4*3*2
43 NALINI 39 IDC-NOS II + - - + - T3N1M0 6*5*3
44 MEGALA 47 IDC-NOS II - - - + - T2N1M0 4*3*2
44 MANIAMMA 46 IDC-NOS II - - + + - T3N1M0 6*5*4
45 KUPPAMAL 53 IDC-NOS III + - - - + T4bN1M0 5*4*3
46 NALINI 55 IDC-NOS I - - + + - T2N0M0 4*3*2
47 PAPPATHY 29 IDC-NOS II - - + - + T2N0M0 3*2*1
48 PARIMALAM 38 IDC-NOS II - - + + - T3N0M0 6*4*3
49 SAROJA 45 IDC-NOS II - - - + - T2N1M0 6*5*3
50 BEGUM 49 IDC-NOS I - - + + - T1N0M0 2*2*1
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